Lyell Immunopharma, Inc. Payments to Acquire Debt Securities, Available-for-sale
Lyell Immunopharma, Inc. (LYEL) reported Payments to Acquire Debt Securities, Available-for-sale of $90.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- Lyell Immunopharma, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $53.52M, a 33.68% decline year-over-year.
- Lyell Immunopharma, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $37.18M, a 55.95% decline year-over-year.
- Lyell Immunopharma, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $42.80M, a 10.30% increase year-over-year.
- Lyell Immunopharma, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $70.99M, a 45.99% decline year-over-year.
- Lyell Immunopharma, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $278.90M, a 29.34% decline from fiscal 2024.
- Lyell Immunopharma, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $394.71M, a 17.23% decline from fiscal 2023.
- Lyell Immunopharma, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $476.88M, a 17.37% increase from fiscal 2022.
- Lyell Immunopharma, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $406.32M, a 39.67% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $53.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $90.71M 10-Q · filed 2026-08-06 | $133.51M derived: sum of 3 quarters · filed 2026-08-06 | $204.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $37.18M 10-Q · filed 2026-05-06 | $79.98M derived: sum of 2 quarters · filed 2026-05-06 | $150.97M derived: sum of 3 quarters · filed 2026-05-06 | $231.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $42.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $113.79M derived: sum of 2 quarters · filed 2026-03-12 | $194.49M derived: sum of 3 quarters · filed 2026-08-06 | $278.90M 10-K · filed 2026-03-12 |
| 2025-09-30 | $70.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $151.69M derived: sum of 2 quarters · filed 2026-08-06 | $236.10M 10-Q · filed 2025-11-12 | $274.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $80.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $165.11M 10-Q · filed 2026-08-06 | $203.91M derived: sum of 3 quarters · filed 2026-08-06 | $335.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $84.41M 10-Q · filed 2026-05-06 | $123.21M derived: sum of 2 quarters · filed 2026-05-06 | $254.64M derived: sum of 3 quarters · filed 2026-05-06 | $371.11M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $38.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $170.23M derived: sum of 2 quarters · filed 2026-03-12 | $286.70M derived: sum of 3 quarters · filed 2026-03-12 | $394.71M 10-K · filed 2026-03-12 |
| 2024-09-30 | $131.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $247.89M derived: sum of 2 quarters · filed 2025-11-12 | $355.90M 10-Q · filed 2025-11-12 | $612.69M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $116.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $224.47M 10-Q · filed 2025-08-12 | $481.26M derived: sum of 3 quarters · filed 2026-03-12 | $559.54M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $108.01M 10-Q · filed 2025-05-13 | $364.80M derived: sum of 2 quarters · filed 2026-03-12 | $443.08M derived: sum of 3 quarters · filed 2026-03-12 | $476.33M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $256.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $335.06M derived: sum of 2 quarters · filed 2026-03-12 | $368.32M derived: sum of 3 quarters · filed 2026-03-12 | $476.88M 10-K · filed 2026-03-12 |
| 2023-09-30 | $78.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $111.53M derived: sum of 2 quarters · filed 2024-11-07 | $220.09M 10-Q · filed 2024-11-07 | $279.76M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $33.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $141.81M 10-Q · filed 2024-08-07 | $201.48M derived: sum of 3 quarters · filed 2025-03-11 | $362.28M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $108.56M 10-Q · filed 2024-05-06 | $168.23M derived: sum of 2 quarters · filed 2025-03-11 | $329.02M derived: sum of 3 quarters · filed 2025-03-11 | $418.68M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $59.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $220.46M derived: sum of 2 quarters · filed 2025-03-11 | $310.12M derived: sum of 3 quarters · filed 2025-03-11 | $406.32M 10-K · filed 2025-03-11 |
| 2022-09-30 | $160.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $250.45M derived: sum of 2 quarters · filed 2023-11-07 | $346.65M 10-Q · filed 2023-11-07 | $480.57M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $89.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $185.85M 10-Q · filed 2023-08-08 | $319.78M derived: sum of 3 quarters · filed 2024-02-28 | $595.09M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $96.20M 10-Q · filed 2023-05-04 | $230.12M derived: sum of 2 quarters · filed 2024-02-28 | $505.43M derived: sum of 3 quarters · filed 2024-02-28 | $721.37M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $133.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $409.24M derived: sum of 2 quarters · filed 2024-02-28 | $625.17M derived: sum of 3 quarters · filed 2024-02-28 | $673.47M 10-K · filed 2024-02-28 |
| 2021-09-30 | $275.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $491.25M derived: sum of 2 quarters · filed 2022-11-08 | $539.54M 10-Q · filed 2022-11-08 | $680.96M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $215.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $264.23M 10-Q · filed 2022-08-04 | $405.65M derived: sum of 3 quarters · filed 2023-02-28 | $656.05M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $48.29M 10-Q · filed 2022-05-10 | $189.71M derived: sum of 2 quarters · filed 2023-02-28 | $440.11M derived: sum of 3 quarters · filed 2023-02-28 | |
| 2020-12-31 | $141.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $391.82M derived: sum of 2 quarters · filed 2023-02-28 | $864.91M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $250.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $723.49M 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $473.09M 10-Q · filed 2021-08-12 | |||
| 2019-12-31 | $610.84M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |